News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
41,904 Results
Type
Article (2160)
Company Profile (3)
Press Release (39741)
Section
Business (10419)
Career Advice (9)
Deals (2117)
Drug Delivery (2)
Drug Development (11599)
Employer Resources (2)
FDA (1487)
Job Trends (597)
News (25071)
Policy (2633)
Tag
Academia (56)
Accelerated approval (1)
Allergies (2)
Alliances (2293)
ALS (30)
Alzheimer's disease (137)
Antibody-drug conjugate (ADC) (6)
Approvals (1480)
Artificial intelligence (1)
Bankruptcy (11)
Best Places to Work (516)
Biosimilars (2)
Biotechnology (3)
Bladder cancer (3)
Brain cancer (9)
Breast cancer (14)
Cancer (239)
Cardiovascular disease (12)
Career advice (8)
CAR-T (13)
Cell therapy (46)
Clinical research (9969)
Collaboration (36)
Compensation (6)
Complete response letters (3)
COVID-19 (71)
CRISPR (2)
C-suite (15)
Cystic fibrosis (17)
Data (281)
Diabetes (12)
Diagnostics (131)
Drug discovery (11)
Drug pricing (4)
Duchenne muscular dystrophy (25)
Earnings (5352)
Editorial (2)
Employer resources (2)
Events (6637)
Executive appointments (35)
FDA (1727)
Friedreich's ataxia (1)
Funding (45)
Gene editing (13)
Gene therapy (55)
GLP-1 (30)
Government (255)
Grass and pollen (1)
Guidances (1)
Healthcare (1098)
Huntington's disease (4)
IgA nephropathy (4)
Immunology and inflammation (6)
Indications (2)
Infectious disease (79)
Inflammatory bowel disease (5)
Inflation Reduction Act (2)
Intellectual property (12)
Interviews (1)
IPO (1198)
IRA (4)
Job creations (110)
Job search strategy (8)
Layoffs (24)
Legal (170)
Liver cancer (19)
Lung cancer (41)
Lymphoma (25)
Management (2)
Manufacturing (13)
MASH (2)
Medical device (153)
Medtech (153)
Mergers & acquisitions (956)
Metabolic disorders (22)
Multiple sclerosis (6)
NASH (1)
Neurodegenerative disease (16)
Neuroscience (206)
NextGen: Class of 2025 (245)
Non-profit (94)
Obesity (8)
Opinion (13)
Ovarian cancer (13)
Pain (6)
Pancreatic cancer (15)
Parkinson's disease (12)
Patents (16)
Patient recruitment (14)
People (2673)
Pharmaceutical (1)
Phase I (2938)
Phase II (5039)
Phase III (3340)
Pipeline (147)
Policy (6)
Postmarket research (99)
Preclinical (745)
Prostate cancer (10)
Radiopharmaceuticals (14)
Rare diseases (89)
Real estate (128)
Regulatory (2465)
Research institute (80)
Rett syndrome (2)
RSV (1)
Schizophrenia (4)
Series A (4)
Series B (4)
Sickle cell disease (6)
Spinal muscular atrophy (77)
Sponsored (3)
Startups (164)
Stomach cancer (1)
Supply chain (4)
Vaccines (9)
Weight loss (1)
Women's health (1)
Date
Today (9)
Last 7 days (66)
Last 30 days (227)
Last 365 days (2899)
2025 (937)
2024 (3104)
2023 (3647)
2022 (4464)
2021 (4386)
2020 (3922)
2019 (2758)
2018 (2065)
2017 (2856)
2016 (2506)
2015 (3099)
2014 (1880)
2013 (982)
2012 (958)
2011 (869)
2010 (801)
Location
Africa (11)
Arizona (1)
Arkansas (1)
Asia (3008)
Australia (437)
California (508)
Canada (130)
China (41)
Colorado (8)
Connecticut (36)
Delaware (8)
Europe (9670)
Florida (93)
Georgia (10)
Idaho (1)
Illinois (25)
Indiana (6)
Japan (9)
Kansas (2)
Kentucky (1)
Maryland (82)
Massachusetts (358)
Michigan (11)
Missouri (5)
Montana (7)
Nevada (24)
New Hampshire (1)
New Jersey (176)
New York (124)
North Carolina (74)
Northern California (243)
Ohio (7)
Oregon (2)
Pennsylvania (145)
South America (28)
Southern California (180)
Tennessee (3)
Texas (110)
United States (1874)
Utah (3)
Virginia (53)
Washington D.C. (9)
Washington State (50)
41,904 Results for "swedish orphan biovitrum".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ) - November 30, 2023
Swedish Orphan Biovitrum AB has, as previously announced, carried out a share issue of series C shares, which has resulted in changes in the number of shares and votes in Sobi.
November 30, 2023
·
1 min read
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ) - September 29, 2023
Swedish Orphan Biovitrum AB has, as previously announced, carried out a rights issue of common shares, which has resulted in changes in the number of shares and votes in Sobi.
September 29, 2023
·
1 min read
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting, to be held on Tuesday, 15 August 2023 at 10.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden.
July 18, 2023
·
12 min read
Deals
New number of shares and votes in Swedish Orphan Biovitrum AB (publ) - June 30, 2023
As per 30 June 2023 , the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 311,336,796 shares.
June 30, 2023
·
1 min read
Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ) - March 30, 2023
The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting, to be held on Tuesday, 9 May 2023 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
March 30, 2023
·
43 min read
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
As per 30 September 2022, the total number of shares in Swedish Orphan Biovitrum AB amounts to 309,804,782 shares.
September 30, 2022
·
1 min read
Business
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB announced its report for the first quarter 2024.
April 25, 2024
·
3 min read
Bulletin from Sobi’s Annual General Meeting (AGM)
The Swedish Orphan Biovitrum AB AGM was convened on 14 May 2024. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:.
May 14, 2024
·
3 min read
Bo Jesper Hansen proposed as new Chairman of the Board of Swedish Orphan Biovitrum AB (publ) ahead of the Annual General Meeting in 2023
As previously communicated, Håkan Björklund, the current Chairman of the Board of Swedish Orphan Biovitrum AB (publ) (Sobi®), has announced that he will not be available for re-election at the company’s Annual General Meeting in 2023.
November 18, 2022
·
2 min read
Business
Swedish Orphan Biovitrum AB (publ)'s Chairman of the Board Håkan Björklund will not be available for re-election at the Annual General Meeting 2023
Håkan Björklund, the current Chairman of the Board of Swedish Orphan Biovitrum AB, has notified the Nomination Committee that he is not available for re-election at the Annual General Meeting 2023.
October 31, 2022
·
1 min read
1 of 4,191
Next
